CN115087749A - 用于通过分析循环肿瘤dna进行分子疾病评定的方法和系统 - Google Patents

用于通过分析循环肿瘤dna进行分子疾病评定的方法和系统 Download PDF

Info

Publication number
CN115087749A
CN115087749A CN202080094820.5A CN202080094820A CN115087749A CN 115087749 A CN115087749 A CN 115087749A CN 202080094820 A CN202080094820 A CN 202080094820A CN 115087749 A CN115087749 A CN 115087749A
Authority
CN
China
Prior art keywords
subject
tumor
sequencing
methylation
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080094820.5A
Other languages
English (en)
Chinese (zh)
Inventor
亚历克斯·罗伯逊
尼尔·彼得曼
尼克·兰伯特
哈洛克·泰兹坎
罗希思·斯里瓦斯
彼得·乔治
杰森·克洛斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nexant Biological Co
Original Assignee
Nexant Biological Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexant Biological Co filed Critical Nexant Biological Co
Publication of CN115087749A publication Critical patent/CN115087749A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/10—Ploidy or copy number detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202080094820.5A 2019-12-24 2020-12-23 用于通过分析循环肿瘤dna进行分子疾病评定的方法和系统 Pending CN115087749A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962953368P 2019-12-24 2019-12-24
US62/953,368 2019-12-24
US202062993564P 2020-03-23 2020-03-23
US62/993,564 2020-03-23
PCT/US2020/066976 WO2021133993A2 (en) 2019-12-24 2020-12-23 Methods and systems for molecular disease assessment via analysis of circulating tumor dna

Publications (1)

Publication Number Publication Date
CN115087749A true CN115087749A (zh) 2022-09-20

Family

ID=76575344

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080094820.5A Pending CN115087749A (zh) 2019-12-24 2020-12-23 用于通过分析循环肿瘤dna进行分子疾病评定的方法和系统

Country Status (8)

Country Link
US (1) US20230135171A1 (cg-RX-API-DMAC7.html)
EP (1) EP4081665A4 (cg-RX-API-DMAC7.html)
JP (2) JP7897794B2 (cg-RX-API-DMAC7.html)
CN (1) CN115087749A (cg-RX-API-DMAC7.html)
AU (1) AU2020414737A1 (cg-RX-API-DMAC7.html)
CA (1) CA3165763A1 (cg-RX-API-DMAC7.html)
TW (1) TWI893039B (cg-RX-API-DMAC7.html)
WO (1) WO2021133993A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118448038A (zh) * 2024-04-26 2024-08-06 天津大学 一种基于多组学动态ctDNA监测食管鳞状细胞癌疗效的方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11078475B2 (en) 2016-05-03 2021-08-03 Sinai Health System Methods of capturing cell-free methylated DNA and uses of same
US12592321B2 (en) 2020-06-19 2026-03-31 University Health Network Cancer detection and classification using methylome analysis
CN118234871A (zh) * 2021-07-27 2024-06-21 牛津大学校长、教师和学者 与用于细胞游离dna的tet辅助吡啶硼烷测序相关的组合物和方法
US20230092508A1 (en) * 2021-09-20 2023-03-23 Droplet Biosciences, Inc. Methods for disease assessment using drain fluid
WO2023092097A1 (en) * 2021-11-19 2023-05-25 Foundation Medicine, Inc. Fragment consensus methods for ultrasensitive detection of aberrant methylation
CN114703284A (zh) * 2022-04-15 2022-07-05 北京莱盟君泰国际医疗技术开发有限公司 一种血液游离dna甲基化定量检测方法及其应用
KR102789317B1 (ko) * 2023-10-06 2025-04-02 (주)지놈포미 고심도 세포 유리 핵산 시퀀싱 기반의 질병 조기 검출 장치 및 방법
EP4790149A1 (en) * 2023-10-06 2026-08-12 Genome4Me, Inc. Apparatus and method for early disease detection based on high-depth cell-free nucleic acid sequencing
CN117987556B (zh) * 2024-02-23 2026-07-14 上海小荷医学检验实验室有限公司 用于确定肿瘤组织的目标CpG位点的甲基化水平的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106795562A (zh) * 2014-07-18 2017-05-31 香港中文大学 Dna混合物中的组织甲基化模式分析
CN110168099A (zh) * 2016-06-07 2019-08-23 加利福尼亚大学董事会 用于疾病和病症分析的无细胞dna甲基化模式
US20190316209A1 (en) * 2018-04-13 2019-10-17 Grail, Inc. Multi-Assay Prediction Model for Cancer Detection
US20190371428A1 (en) * 2017-01-20 2019-12-05 Sequenom, Inc. Methods for non-invasive assessment of copy number alterations
WO2019236906A1 (en) * 2018-06-06 2019-12-12 Lexent Bio, Inc. Methods for fingerprinting of biological samples

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019018272A2 (pt) 2017-03-02 2020-07-28 Youhealth Oncotech, Limited marcadores metilação para diagnosticar hepatocelular carcinoma e câncer
WO2019200410A1 (en) * 2018-04-13 2019-10-17 Freenome Holdings, Inc. Machine learning implementation for multi-analyte assay of biological samples

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106795562A (zh) * 2014-07-18 2017-05-31 香港中文大学 Dna混合物中的组织甲基化模式分析
CN110168099A (zh) * 2016-06-07 2019-08-23 加利福尼亚大学董事会 用于疾病和病症分析的无细胞dna甲基化模式
US20190371428A1 (en) * 2017-01-20 2019-12-05 Sequenom, Inc. Methods for non-invasive assessment of copy number alterations
US20190316209A1 (en) * 2018-04-13 2019-10-17 Grail, Inc. Multi-Assay Prediction Model for Cancer Detection
WO2019236906A1 (en) * 2018-06-06 2019-12-12 Lexent Bio, Inc. Methods for fingerprinting of biological samples

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDREW A. DAVIS等: "Early assessment of molecular progression and response by whole-genome circulating tumor DNA in advanced solid tumors", MEDRXIV, 25 November 2019 (2019-11-25), pages 1 - 22 *
XU ZHAI等: "Methylation of RASSF1A and CDH13 Genes in Individualized Chemotherapy for Patients with Non-small Cell Lung Cancer", ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol. 15, no. 12, 31 December 2014 (2014-12-31), pages 4925 - 4928 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118448038A (zh) * 2024-04-26 2024-08-06 天津大学 一种基于多组学动态ctDNA监测食管鳞状细胞癌疗效的方法

Also Published As

Publication number Publication date
JP2026049725A (ja) 2026-03-18
WO2021133993A2 (en) 2021-07-01
JP2023508947A (ja) 2023-03-06
TW202138566A (zh) 2021-10-16
JP7897794B2 (ja) 2026-07-30
AU2020414737A1 (en) 2022-07-14
US20230135171A1 (en) 2023-05-04
TWI893039B (zh) 2025-08-11
CA3165763A1 (en) 2021-07-01
WO2021133993A3 (en) 2021-09-30
EP4081665A2 (en) 2022-11-02
EP4081665A4 (en) 2024-01-10

Similar Documents

Publication Publication Date Title
TWI893039B (zh) 透過循環腫瘤dna分析之分子疾病評估之方法及系統
JP7851251B2 (ja) 遺伝子サンプリングにおける統計的バイアスの軽減
CN113260633A (zh) 用于癌症免疫疗法的诊断方法和组合物
US20240410016A1 (en) Cd274 rearrangements as predictors of response to immune checkpoint inhibitor therapy
US20240110230A1 (en) Biomarkers for cancer treatment
CN108379586A (zh) 对cars的抗肿瘤活性的毒性管理
US20240384350A1 (en) Methods of treating cancer with kinase inhibitors
JP2024509360A (ja) がんにおける方法およびバイオマーカー
US20250084482A1 (en) Methods of using somatic hla-i loh to predict response of immune checkpoint inhibitor-treated patients with lung cancer
JP2023510113A (ja) 神経膠芽腫を処置するための方法
US20240263240A1 (en) Cd274 mutations for cancer treatment
CN118414439A (zh) 通过液体活检检测的新型激酶融合
US20240417802A1 (en) Immunotherapeutic methods for treating cancer
CN117794944A (zh) 靶向肿瘤抗原的方法和材料
US20240108623A1 (en) Methods of treating cancer with poziotinib
WO2025024258A2 (en) Ebv status as a predictor of response to immunotherapy
WO2025122856A1 (en) Use of fibroblast growth factor receptor 3 mutations and tumor mutational burden to predict response to immunotherapies
US20210230545A1 (en) Use of il-12 to alter epigenetic effector programs in cd8 t cells
HK40058894A (en) Diagnostic methods and compositions for cancer immunotherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination